NSE / BSEHealthcare
β‚Ή863.45-3.00-0.35%
P/E10.3Mkt Capβ‚Ή15.58 K CrEV/EBITDA8.8

Natco Pharma Ltd.

P/E10.3Mkt Capβ‚Ή15.58 K CrEV/EBITDA8.8
Company Profile

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 26 Aug 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–² 0.94% over 1Y
Monthly Returns

Historically, Apr has averaged the highest return (+6.4%); Sep the lowest (-5.4%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-7.5%Negative MonthJan 2026: -7.54%+18.3%Positive MonthFeb 2026: +18.30%-1.3%Neutral MonthMar 2026: -1.35%+12.4%Positive MonthApr 2026: +12.39%-7.2%Negative MonthMay 2026: -7.22%-8.4%Negative MonthJun 2026: -8.35%-1.3%Neutral MonthJul 2026: -1.29%-6.1%*Negative MonthAug 2026: -6.13%β€”β€”β€”β€”
2025-15.2%Negative MonthJan 2025: -15.25%-34.4%Negative MonthFeb 2025: -34.37%+3.4%Positive MonthMar 2025: +3.38%+6.7%Positive MonthApr 2025: +6.68%+3.8%Positive MonthMay 2025: +3.82%+5.0%Positive MonthJun 2025: +4.96%+2.8%Positive MonthJul 2025: +2.85%-9.7%Negative MonthAug 2025: -9.66%-7.7%Negative MonthSep 2025: -7.67%+3.1%Positive MonthOct 2025: +3.10%+7.1%Positive MonthNov 2025: +7.08%+2.9%Positive MonthDec 2025: +2.87%
2024+6.6%Positive MonthJan 2024: +6.64%+14.9%Positive MonthFeb 2024: +14.92%-4.3%Negative MonthMar 2024: -4.29%+7.0%Positive MonthApr 2024: +7.00%-2.0%Neutral MonthMay 2024: -1.96%+16.9%Positive MonthJun 2024: +16.85%+16.7%Positive MonthJul 2024: +16.68%+13.0%Positive MonthAug 2024: +12.98%-7.6%Negative MonthSep 2024: -7.62%-1.2%Neutral MonthOct 2024: -1.22%-2.0%Neutral MonthNov 2024: -1.96%+0.9%Neutral MonthDec 2024: +0.86%
2023-5.0%Negative MonthJan 2023: -5.04%+0.9%Neutral MonthFeb 2023: +0.93%+4.7%Positive MonthMar 2023: +4.75%+1.9%Neutral MonthApr 2023: +1.94%+7.6%Positive MonthMay 2023: +7.62%+12.1%Positive MonthJun 2023: +12.06%+20.5%Positive MonthJul 2023: +20.48%+9.4%Positive MonthAug 2023: +9.44%-4.4%Negative MonthSep 2023: -4.43%-8.4%Negative MonthOct 2023: -8.39%-1.0%Neutral MonthNov 2023: -0.98%+2.4%Positive MonthDec 2023: +2.41%
2022+0.5%Neutral MonthJan 2022: +0.51%-4.5%Negative MonthFeb 2022: -4.47%-12.8%Negative MonthMar 2022: -12.76%+3.9%Positive MonthApr 2022: +3.95%-12.1%Negative MonthMay 2022: -12.09%-6.4%Negative MonthJun 2022: -6.44%+5.4%Positive MonthJul 2022: +5.43%-9.8%Negative MonthAug 2022: -9.79%-1.6%Neutral MonthSep 2022: -1.63%-0.8%Neutral MonthOct 2022: -0.83%-6.6%Negative MonthNov 2022: -6.58%+0.0%Neutral MonthDec 2022: +0.04%
2021β€”β€”β€”β€”β€”+6.3%Positive MonthJun 2021: +6.29%-9.8%Negative MonthJul 2021: -9.83%-7.2%Negative MonthAug 2021: -7.24%-5.6%Negative MonthSep 2021: -5.63%-7.2%Negative MonthOct 2021: -7.23%+1.3%Neutral MonthNov 2021: +1.32%+7.9%Positive MonthDec 2021: +7.94%
AvgΒ±SD-4.1%Β±7.4%-0.9%Β±18.7%-2.1%Β±6.3%+6.4%Β±3.5%-2.0%Β±7.1%+4.2%Β±9.1%+5.7%Β±10.3%-1.7%Β±9.3%-5.4%Β±2.2%-2.9%Β±4.3%-0.2%Β±4.5%+2.8%Β±2.8%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 0.956x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή4.09 K Crβ–² 14.7%
EBITDA Growthβ€”
Net Profitβ‚Ή1.85 K Crβ–² 41.5%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 700.0%
Revenue CAGR 5Y14.8%
EBITDA CAGR 5Y19.9%
Net Profit CAGR 5Y22.5%
NP Growth 1Y41.5%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή4.09 K Crβ€”β‚Ή1.85 K Crβ€”β€”25.2%14.7%41.5%
Mar 2024β‚Ή3.57 K Crβ€”β‚Ή1.31 K Crβ€”β€”23.4%51.8%105.2%
Mar 2023β‚Ή2.35 K Crβ€”β‚Ή637.00 Crβ€”β€”13.5%33.0%358.3%
Mar 2022β‚Ή1.77 K Crβ€”β‚Ή139.00 Crβ€”β€”3.3%6.9%-55.2%
Mar 2021β‚Ή1.65 K Crβ€”β‚Ή310.00 Crβ€”β€”7.6%-7.6%-34.6%
Mar 2020β‚Ή1.79 K Crβ€”β‚Ή474.00 Crβ€”β€”12.3%-9.9%-28.9%
Mar 2019β‚Ή1.99 K Crβ€”β‚Ή667.00 Crβ€”β€”18.7%-5.0%-4.4%
Mar 2018β‚Ή2.09 K Crβ€”β‚Ή698.00 Crβ€”β€”22.3%6.8%41.0%
Mar 2017β‚Ή1.96 K Crβ€”β‚Ή495.00 Crβ€”β€”29.1%84.9%181.3%
Mar 2016β‚Ή1.06 K Crβ€”β‚Ή176.00 Crβ€”β€”13.2%47.9%15.0%

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales6227161,0591,9582,0911,9861,7901,6541,7682,3513,5694,0944,022
Total Expenses4364877781,2661,1631,1701,2121,2361,5551,5061,9291,9502,339
EBIT / Operating Profit1872292816929288165784182138451,6402,1441,683
OPM %30%32%26%35%44%41%32%25%12%36%46%52%42%
Other Income16-21313391301241019586102321383
Finance Costs3430221815192111139142026
Depreciation & Amortisation27425054668098115138151172220239
Profit Before Tax1411542226348888475833921567711,5552,2261,800
Tax %22%1%20%22%21%21%19%21%11%17%16%17%-
Net Profit / PAT1101531764956986674743101396371,3071,8501,518
EPS (β‚Ή)6.669.2010.1328.3937.8436.4826.0616.977.6234.9072.95103.3184.75
Dividend Payout %15%11%12%24%22%17%26%31%59%16%13%6%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
Natco Pharma Ltd.this co.β‚Ή15.58 K Crβ‚Ή4.09 K Cr10.301.898.7714.7%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of Natco Pharma Ltd. and the metrics that matter.

Browse the full Equiscale Academy